Vaxess Technologies: Funding, Investors & Team (Sep 2026)
Vaxess Technologies is working on creating the MIMIX™ sustained release patch technology, which offers a simple and efficient method for delivering vaccines and treatments. This controlled release system mimics the body's natural response to infection, resulting in a gradual and powerful immune response that enhances the effectiveness of vaccines. Additionally, the patch is designed to remain stable without needing refrigeration, making it ideal for use in areas with limited resources.
Vaxess Technologies has raised $101M across 7 funding rounds on record, the most recent an undisclosed round of $9.0M announced in Apr 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vaxess Technologies Company Profile and Key Stats
Latest funding round on record: Apr 2025.
Vaxess Technologies Funding Rounds
Vaxess Technologies raised $25.3M in an undisclosed round announced in May 2021.
1.5 years later, a Series B of $27.0M was announced in Nov 2022.
2 months later, a Series B of $10.0M was announced in Jan 2023.
6 months later, an undisclosed round of $9.1M was announced in Jul 2023.
2 months later, an undisclosed round of $9.0M was announced in Sep 2023.
8 months later, an undisclosed round of $12.0M was announced in May 2024.
11 months later, an undisclosed round of $9.0M was announced in Apr 2025.
Vaxess Technologies Founders and Leadership Team
Contact details for the Vaxess Technologies team: 3 of 3 have an email address on file.
Start 14-day free trial →Vaxess Technologies Funding Compared to Other Biotechnology Startups
Vaxess Technologies' latest round of $9.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vaxess Technologies in Biotechnology and Cambridge
Companies Similar to Vaxess Technologies
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Vaxess Technologies Funding FAQs
What does Vaxess Technologies do?
Vaxess Technologies is working on creating the MIMIX™ sustained release patch technology, which offers a simple and efficient method for delivering vaccines and treatments. This controlled release system mimics the body's natural response to infection, resulting in a gradual and powerful immune response that enhances the effectiveness of vaccines. Additionally, the patch is designed to remain stable without needing refrigeration, making it ideal for use in areas with limited resources.
How much funding has Vaxess Technologies raised?
Vaxess Technologies has raised $101M across 7 rounds on record. The most recent is an undisclosed round of $9.0M announced in Apr 2025.
When did Vaxess Technologies last raise funding?
Vaxess Technologies' most recent funding round on record is an undisclosed round of $9.0M, announced in Apr 2025.
Who founded Vaxess Technologies?
FundedIQ lists Kathryn Kosuda (Founder), Livio Valenti (Founder) at Vaxess Technologies.
Who is the CEO of Vaxess Technologies?
Michael Schrader is listed as CEO at Vaxess Technologies.
Where is Vaxess Technologies headquartered?
Vaxess Technologies is based in Cambridge, Massachusetts, United States.
How many employees does Vaxess Technologies have?
Vaxess Technologies is in the 51-100 employee band.
How does Vaxess Technologies' funding compare to other Biotechnology startups?
Vaxess Technologies' latest round of $9.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Vaxess Technologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vaxess Technologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.